Catalyst Biosciences (NASDAQ:CBIO) has been assigned a $19.00 price objective by equities researchers at B. Riley in a report issued on Monday, December 18th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price target would suggest a potential upside of 27.26% from the stock’s previous close.
Separately, Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Wednesday, November 8th.
Catalyst Biosciences (NASDAQ:CBIO) traded up $0.32 during mid-day trading on Monday, reaching $14.93. 137,746 shares of the company traded hands, compared to its average volume of 213,493. Catalyst Biosciences has a 1 year low of $3.11 and a 1 year high of $18.88. The company has a market cap of $86.10, a PE ratio of -1.14 and a beta of 1.91.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC acquired a new position in Catalyst Biosciences in the 2nd quarter worth $103,000. Bank of New York Mellon Corp acquired a new position in Catalyst Biosciences in the 2nd quarter worth $107,000. Zacks Investment Management acquired a new position in Catalyst Biosciences in the 2nd quarter worth $147,000. Vanguard Group Inc. boosted its stake in Catalyst Biosciences by 294.1% in the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Catalyst Biosciences in the 2nd quarter worth $372,000. 22.96% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/11/catalyst-biosciences-cbio-pt-set-at-19-00-by-b-riley.html.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.